Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and Refractory Multiple Myeloma (RRMM)”

142 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 142 results

Testing effectiveness (Phase 2)WithdrawnNCT03221634
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC
Very early researchNot Yet RecruitingNCT07234721
What this trial is testing

SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 9
Testing effectiveness (Phase 2)WithdrawnNCT03856112
What this trial is testing

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myelomat(11;14) Negative
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT03650491
What this trial is testing

FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma With Failed Remission
Fortis Therapeutics, Inc. 31
Testing effectiveness (Phase 2)Looking for participantsNCT05972135
What this trial is testing

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Study completedNCT03194867
What this trial is testing

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Who this might be right for
Plasma Cell Myeloma
Sanofi 109
Large-scale testing (Phase 3)WithdrawnNCT06232707
What this trial is testing

Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene
Not applicableUnknownNCT05297240
What this trial is testing

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Who this might be right for
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
PETHEMA Foundation 170
Early research (Phase 1)Not Yet RecruitingNCT07407010
What this trial is testing

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 10
Not applicableStudy completedNCT03477643
What this trial is testing

Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and Refractory Multiple Myeloma
PETHEMA Foundation 110
Testing effectiveness (Phase 2)Study completedNCT04191616
What this trial is testing

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 54
Testing effectiveness (Phase 2)Looking for participantsNCT07382739
What this trial is testing

Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Who this might be right for
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
M.D. Anderson Cancer Center 34
Early research (Phase 1)WithdrawnNCT04918511
What this trial is testing

OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma

Who this might be right for
Relapse Multiple MyelomaMultiple Myeloma
Oncopeptides AB
Early research (Phase 1)UnknownNCT05698303
What this trial is testing

Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd. 12
Not applicableLooking for participantsNCT07051850
What this trial is testing

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Who this might be right for
Multiple Myeloma, RelapsedMultiple Myeloma (MM)
Sung-Soo Park 174
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05909826
What this trial is testing

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Dong-A University Hospital 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT07150104
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 14
Testing effectiveness (Phase 2)Ended earlyNCT04776018
What this trial is testing

TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda 27
Large-scale testing (Phase 3)Study completedNCT03110562
What this trial is testing

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc 402
Testing effectiveness (Phase 2)Active Not RecruitingNCT05911321
What this trial is testing

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Who this might be right for
Multiple MyelomaRelapseRefractory+2 more
UNC Lineberger Comprehensive Cancer Center 6
Load More Results